Tirzepatide, sold under the brand names Zepbound and Mounjaro, is a prescription medication that works for weight loss by reducing appetite and increasing satiety. Administered as a once-weekly ...

CEO David Ricks said the sale of cheaper, off-brand versions of the company’s blockbuster weight loss drug isn’t having a ...

On Friday, Novo Nordisk A/S (NYSE:NVO) released headline results from part 1 of the ongoing ESSENCE Phase 3 trial, a 240-week ...

One big idea has loomed over healthcare stocks over the past two years: Demand for the new GLP-1 weight loss medicines from ...

These drugs have gained widespread attention in the media, with public figures like Chelsea Handler and Elon Musk openly ...

Eli Lilly and Company disappointed with missed earnings, lower guidance. Click here for my review of LLY Q3 earnings and a ...

Q3 sales in weight loss drugs Mounjaro and Zepbound were more than 20% lower than consensus analyst forecasts, spooking investors.

Millions of Americans rely on a new class of medications to manage chronic conditions like diabetes and obesity, with ...

(Reuters) -Eli Lilly missed Wall Street estimates for third-quarter profit on Wednesday, hurt by higher manufacturing costs ...

Compared with long-acting insulins, tirzepatide was associated with superior glycemic control outcomes among adults with type 2 diabetes. Tirzepatide demonstrates greater efficacy than long-acting and ...

A new report found people selling leftover weight loss drugs, like Ozempic or Mounjaro, on Facebook. Doctors are ...

It also lifted guidance by $2 billion after the first quarter, citing booming demand for its tirzepatide products. In making the latest adjustment, Lilly cited its "prudent" rollout as it works to ...